• Home
  • Science
  • Therapeutic Strategy
  • Team
  • News
  • Contact
Contact

Recent Posts

  • Visgenx to Present at the 4th Annual Dry AMD Therapeutic Development Summit
  • Visgenx Announces Issuance of a U.S. Patent Claiming Compositions of Candidate ELOVL2 Gene Therapy
  • Visgenx Poster: Advancing Next Generation Therapies, West Coast Symposium
  • Visgenx Presents Poster at the Cell and Gene Therapy: Advancing Next Generation Therapies, West Coast Symposium
  • Visgenx Announces Positive Results from a Key Translational Study for its Gene Therapy Candidate for Dry AMD

Archives

  • November 2023
  • October 2023
  • September 2023
  • June 2023
  • May 2023

Categories

  • Uncategorized

Archives

  • November 2023
  • October 2023
  • September 2023
  • June 2023
  • May 2023

Author: chris

15.11.2023
Visgenx to Present at the 4th Annual Dry AMD Therapeutic Development Summit
»
25.10.2023
Visgenx Announces Issuance of a U.S. Patent Claiming Compositions of Candidate ELOVL2...
»
11.09.2023
Visgenx Poster: Advancing Next Generation Therapies, West Coast Symposium
»
11.09.2023
Visgenx Presents Poster at the Cell and Gene Therapy: Advancing Next Generation...
»
29.06.2023
Visgenx Announces Positive Results from a Key Translational Study for its Gene...
»
05.06.2023
Visgenx Appoints William Pedranti as Chief Executive Officer
»
24.05.2023
Attending BIO 2023? Click below to send Visgenx a meeting request in the...
»
15.05.2023
Visgenx to present at the American Society of Gene and Cell Therapy...
»
Visgenx, Inc. © 2023. All Rights Reserved.
Privacy Policy Terms of Use
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy